Drug Trial Radar · NCT04909164
The Prospective Non-randomized Case-control Study From Real-world Lung Cancer Patients
Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,519
Actual
Start
Jun 15, 2021
Primary completion
Dec 31, 2025
Study completion Jul 30, 2026
Sponsor
- Lead sponsor
- Myung-Ju AhnAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Evidence-Based Healthcare Collaborating Agency
- First posted
- Jun 1, 2021
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The pragmatic clinical trial to elucidate optimal target population of immunotherapy from real-world lung cancer patients
Conditions
- Non-small Cell Lung Cancer (NSCLC)
Interventions
Immunnotherapy groupDrug
Eligible patients are those who receive reimbursed immunotherapy or cytotoxic chemotherapy after failure of platinum-based chemotherapy per current health insurance reimbursement criteria.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survivalTime frame: Up to 3 years
- Overall-survivalTime frame: Up to 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.